Literature DB >> 10915081

C3 as substrate for adhesion of Streptococcus pneumoniae.

B L Smith1, M K Hostetter.   

Abstract

The ability of choline-binding protein A (CbpA) of Streptococcus pneumoniae to bind the third component of complement (C3) suggests possible interactions with opsonic C3 in the bloodstream or with C3 secreted by epithelial cells. The latter possibility was investigated by measuring C3 in supernatants of resting and cytokine-activated monolayers of type II pulmonary epithelial cells (A549 cells). Expression of C3 on the epithelial cell surface was confirmed by immunofluorescence. Epithelially produced C3 bound to CbpA, as determined by Western blot test. cbpa(-) mutants and lysates therefrom failed to bind C3, were completely deficient in adhesion to a matrix in which C3 was the sole substrate, and demonstrated a moderate yet significant decrease in adhesion to type II pulmonary epithelial cells. These results confirm the interaction of the pneumococcal protein CbpA and its substrate, C3, in 2 in vitro models of adhesion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915081     DOI: 10.1086/315722

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae.

Authors:  Edwin Swiatlo; Franklin R Champlin; Steven C Holman; W William Wilson; James M Watt
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

3.  RR06 activates transcription of spr1996 and cbpA in Streptococcus pneumoniae.

Authors:  Zhuo Ma; Jing-Ren Zhang
Journal:  J Bacteriol       Date:  2007-01-12       Impact factor: 3.490

4.  Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.

Authors:  Sonia Manco; Fidelma Hernon; Hasan Yesilkaya; James C Paton; Peter W Andrew; Aras Kadioglu
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype.

Authors:  Jose Yuste; Suneeta Khandavilli; Naadir Ansari; Kairya Muttardi; Laura Ismail; C Hyams; Jeffrey Weiser; Timothy Mitchell; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

6.  Pneumococcal wall teichoic acid is required for the pathogenesis of Streptococcus pneumoniae in murine models.

Authors:  Hongmei Xu; Libin Wang; Jian Huang; Yanqing Zhang; Feng Ma; Jianmin Wang; Wenchun Xu; Xuemei Zhang; Yibing Yin; Kaifeng Wu
Journal:  J Microbiol       Date:  2015-01-28       Impact factor: 3.422

7.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15.

Authors:  Thomas G Duthy; Rebecca J Ormsby; Eleni Giannakis; A David Ogunniyi; Uwe H Stroeher; James C Paton; David L Gordon
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Species-specific interaction of Streptococcus pneumoniae with human complement factor H.

Authors:  Ling Lu; Zhuo Ma; T Sakari Jokiranta; Adeline R Whitney; Frank R DeLeo; Jing-Ren Zhang
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  C3 promotes clearance of Klebsiella pneumoniae by A549 epithelial cells.

Authors:  Beatriz de Astorza; Guadalupe Cortés; Catalina Crespí; Carles Saus; José María Rojo; Sebastián Albertí
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.